FDA panel rejects sodium oxybate for fibromyalgia.
Sodium oxybate is the sodium salt of gamma hy-droxybutyrate (GHB), an endogenous neurotransmitter synthesized from gamma aminobutyric acid, and is also known as the "date rape" drug. Sodium oxybate in an oral solution was approved in 2002 for narcolepsy and has been marketed as Xyrem by Jazz Pharmaceuticals, with a risk evaluation and mitigation (REMS) program that tightly controls availability of the drug and includes restricted distribution of the agent through one centralized pharmacy and other measures.
A main concern voiced by panelists and FDA reviewers was if the drug were approved to treat fibromyalgia, its use would increase substantially--and its availability as a street drug could increase markedly, despite the controlled distribution.
The panelists were strongly against the company's proposal to use a different commercial name (Rekinla), concentration, and dose. They also opposed a different REMS for the fibromyalgia indication, with distribution through 15 specialized pharmacies, which they said was confusing and would increase the chances of errors.
The company proposed that patients would take two doses, one before going to sleep and the second in the middle of the night, which was also cited as a disadvantage for patients.
In two phase III randomized, double-blind, controlled 14-week studies, two different doses of sodium oxybate were compared with placebo in about 1,000 fibromyalgia patients aged 18 and older, who discontinued opiates, benzodiazepines, muscle relaxants, and other medications or devices before enrollment. A significantly greater proportion of those treated with sodium oxybate (36%-46%) met the primary end point, at least a 30% reduction in pain from baseline to the end of treatment, compared with those on placebo (20%-27%). Adverse events were similar to those observed in Xyrem trials.
Xyrem is also approved in the European Union and Canada for the treatment of symptoms associated with narcolepsy. The company anticipates that the drug would be used to treat up to 120,000 people with fibromyalgia in the United States. The other drugs approved by the FDA for treating fibromyalgia are milnacipran (Savella), pregabalin (Lyrica), and duloxetine (Cymbalta).
The FDA usually follows the advice of its panels. Panelists have been cleared of potential conflicts.
BY ELIZABETH MECHCATIE
FROM A JOINT MEETING OF THE FDA'S ARTHRITIS ADVISORY COMMITTEE AND THE DRUG SAFETY AND RISK MANAGEMENT COMMITTEE
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Date:||Sep 1, 2010|
|Previous Article:||Twice-weekly tai chi eased fibromyalgia.|
|Next Article:||Risk of suicide spurs rimonabant trial to end.|